Table 3.
Preterm birth and perinatal mortality outcomes, by site
| Outcome | Overall | Malaria Negative | Malaria positive | Aspirin – Malaria Interaction p-value | |||
|---|---|---|---|---|---|---|---|
| n/N (%) | PR (95% CI) | N w/o outcome | PR (95% CI) | N w/o outcome | PR (95% CI) | ||
| DRC DRC | |||||||
| Preterm Delivery | |||||||
| Aspirin | 44/227 (19) | 0·98 (0·68, 1·41) | 14/87 (16) | 1·05 (0·53, 2·10) | 30/140 (21) | 0·96 (0·62, 1·48) | 0.84 |
| Placebo | 48/242 (20) | 13/85 (15) | 35/157 (22) | ||||
| Perinatal Mortality | |||||||
| Aspirin | 18/227 (8) | 1·37 (0·70, 2·69) | 3/87 (3) | 0·42 (0·11, 1·57) | 15/140 (11) | 2·40 (1·01, 5·72) | 0.035 |
| Placebo | 14/242 (6) | 7/85 (8) | 7/157 (4) | ||||
| Kenya | |||||||
| Preterm Delivery | |||||||
| Aspirin | 29/329 (9) | 0·95 (0·58, 1·55) | 15/199 (8) | 0·94 (0·48, 1·84) | 14/130 (11) | 0·94 (0·46, 1·92) | 0.99 |
| Placebo | 29/313 (9) | 16/199 (8) | 13/114 (11) | ||||
| Perinatal Mortality | |||||||
| Aspirin | 17/329 (5) | 0·95 (0·49, 1·83) | 7/199 (4) | 0·78 (0·30, 2·05) | 10/130 (8) | 1·10 (0·45, 2·68) | 0.62 |
| Placebo | 17/313 (5) | 9/199 (5) | 8/114 (7) | ||||
| Zambia | |||||||
| Preterm Delivery | |||||||
| Aspirin | 10/168 (6) | 0·76 (0·34, 1·70) | 9/159 (6) | 0·67 (0·30, 1·53) | 1/9 (11) | – | – |
| Placebo | 13/167 (8) | 13/155 (8) | 0/12 (0) | ||||
| Perinatal Mortality | |||||||
| Aspirin | 6/168 (4) | 0·50 (0·19, 1·29) | 6/159 (4) | 0·49 (0·19, 1·27) | 0/9 (0) | – | 1.00 |
| Placebo | 12/167 (7) | 12/155 (8) | 0/12 (0) | ||||
Notes: PR is prevalence ratio
PR was not calculated for cells in which no participants experienced the outcome